Top > Search of International Patents > DNA fragment and use thereof

DNA fragment and use thereof

Foreign code F120006094
File No. S2008-0302
Posted date Jan 6, 2012
Country United States of America
Application number 86599609
Gazette No. 20110023155
Gazette No. 8865669
Date of filing Feb 4, 2009
Gazette Date Jan 27, 2011
Gazette Date Oct 21, 2014
International application number JP2009051907
International publication number WO2009099112
Date of international filing Feb 4, 2009
Date of international publication Aug 13, 2009
Priority data
  • P2008-024071 (Feb 4, 2008) JP
  • 2009WO-JP51907 (Feb 4, 2009) WO
Title DNA fragment and use thereof
Abstract (US8865669)
The invention relates to a DNA consisting of the nucleotide sequence shown in SEQ ID NO: 1, or a nucleotide sequence the same or substantially the same as a partial nucleotide sequence thereof containing at least one HRE consensus sequence, which transiently has a transcription promoting activity in a vascular endothelial cell-specific manner in a hypoxic state, or a vector containing a promoter containing the DNA, and the like.
The prophylaxis and/or treatment, as well as diagnosis, of acute ischemic diseases are enabled by connecting a prophylactic and/or therapeutic gene or a reporter gene to the downstream of the vector and administering same to mammals.
Scope of claims [claim1]
1. A method for promoting vascular endothelial cell-specific transcription of a gene in cells in an acute ischemic stage in a patient, which comprises administrating to the patient by catheter or injection an expression vector comprising a gene operably linked to a promoter such that an effective amount of the expression vector is delivered to the cells in an acute ischemic stage, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 80% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog, and wherein the gene operably linked to the promoter is transiently expressed in the cells in an acute ischemic stage in the patient in a vascular endothelial cell-specific manner, thereby promoting vascular endothelial cell-specific transcription of the gene in the cells in an acute ischemic stage in the patient.
[claim2]
2. The method of claim 1, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 90% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim3]
3. The method of claim 2, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 95% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim4]
4. The method of claim 1, wherein the gene is selected from the group consisting of vascular endothelial growth factor (VEGF), erythropoietin, hepatocyte growth factor (HGF), basic fibroblast growth factor (FGF), endothelial-derived nitric oxide synthase (eNOS), integrin-linked kinase, B-cell lymphoma (Bcl)-2, Bcl-xL, Bclw, and myeloid cell leukemia (Mcl)-1.
[claim5]
5. The method of claim 1, wherein the expression vector is administered to the patient by catheter.
[claim6]
6. The method of claim 1, wherein the expression vector is administered to the patient by injection.
[claim7]
7. The method of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO: 1.
[claim8]
8. The method of claim 7, wherein the expression vector is administered to the patient by catheter.
[claim9]
9. The method of claim 7, wherein the expression vector is administered to the patient by injection.
[claim10]
10. The method of claim 1, wherein the promoter comprises the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim11]
11. The method of claim 10, wherein the expression vector is administered to the patient by catheter.
[claim12]
12. The method of claim 10, wherein the expression vector is administered to the patient by injection.
[claim13]
13. A method for promoting vascular endothelial cell-specific transcription of a gene in cells in an acute ischemic stage in a patient, which comprises administering an expression vector comprising a gene operably linked to a promoter directly to the cells in an acute ischemic stage in the patient, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 80% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog, and wherein the gene operably linked to the promoter is transiently expressed in the cells in an acute ischemic stage in the patient in a vascular endothelial cell-specific manner, thereby promoting vascular endothelial cell-specific transcription of the gene in the cells in an acute ischemic stage in the patient.
[claim14]
14. The method of claim 13, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 90% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim15]
15. The method of claim 14, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 95% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim16]
16. The method of claim 13, wherein the promoter comprises the nucleotide sequence of SEQ ID NO: 1.
[claim17]
17. The method of claim 13, wherein the promoter comprises the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
  • Inventor, and Inventor/Applicant
  • HIROHATA SATOSHI
  • NINOMIYA YOSHIFUMI
  • KUSACHI SHOZO
  • OMER FARUK HATIPOGLU
  • OKAYAMA UNIVERSITY
IPC(International Patent Classification)

PAGE TOP

close
close
close
close
close
close